Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Fabi

Showing results (251-260 of 265) with videos related to

Pageof 27
Sort By:
NPJ Breast Cancer|July 17, 2024
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY studySimone Scagnoli, Simona Pisegna, Angela Toss, et al.
Journal of Translational Medicine|October 16, 2023
The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-worldPatrizio Giacomini, Fabio Valenti, Matteo Allegretti, et al.
JNCI Cancer Spectrum|October 15, 2025
Lifestyle and environmental factors in women carrying BRCA pathogenic variants with and without cancerAlessandra Fabi, Antonio Franco, Laura Cortesi, et al.
Plos One|September 5, 2015
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast CancerStefania Gori, Alessandro Inno, Elena Fiorio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2023
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 TrialsBenedetta Conte, Luca Boni, Giancarlo Bisagni, et al.
Critical Reviews in Oncology/Hematology|June 8, 2025
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus reportFederica Miglietta, Maria Grazia Razeti, Aldo Caltavituro, et al.
Oncotarget|January 8, 2019
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Journal of Cancer Policy|January 14, 2026
Defining the Role and Competencies of the Medical Oncologist in Diagnostic and Therapeutic Care Pathways: Consensus Recommendations from the Italian Association of Medical Oncology (AIOM)Rossana Berardi, Francesca Rossi, Valentina Tarantino, et al.
La Radiologia Medica|July 7, 2026
Request and reporting models for computed tomography in the multidisciplinary management of cancer patients: consensus between the Italian Society of Medical and Interventional Radiology (SIRM) and the Italian Society of Medical Oncology (AIOM)Vincenza Granata, Alessandro Serafini, Roberta Fusco, et al.
Oncotarget|October 24, 2018
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Pageof 27

Showing results (251-260 of 265) with videos related to

Sort By:
Pageof 27
NPJ Breast Cancer|July 17, 2024
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY studySimone Scagnoli, Simona Pisegna, Angela Toss, et al.
Journal of Translational Medicine|October 16, 2023
The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-worldPatrizio Giacomini, Fabio Valenti, Matteo Allegretti, et al.
JNCI Cancer Spectrum|October 15, 2025
Lifestyle and environmental factors in women carrying BRCA pathogenic variants with and without cancerAlessandra Fabi, Antonio Franco, Laura Cortesi, et al.
Plos One|September 5, 2015
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast CancerStefania Gori, Alessandro Inno, Elena Fiorio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2023
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 TrialsBenedetta Conte, Luca Boni, Giancarlo Bisagni, et al.
Critical Reviews in Oncology/Hematology|June 8, 2025
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus reportFederica Miglietta, Maria Grazia Razeti, Aldo Caltavituro, et al.
Oncotarget|January 8, 2019
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Journal of Cancer Policy|January 14, 2026
Defining the Role and Competencies of the Medical Oncologist in Diagnostic and Therapeutic Care Pathways: Consensus Recommendations from the Italian Association of Medical Oncology (AIOM)Rossana Berardi, Francesca Rossi, Valentina Tarantino, et al.
La Radiologia Medica|July 7, 2026
Request and reporting models for computed tomography in the multidisciplinary management of cancer patients: consensus between the Italian Society of Medical and Interventional Radiology (SIRM) and the Italian Society of Medical Oncology (AIOM)Vincenza Granata, Alessandro Serafini, Roberta Fusco, et al.
Oncotarget|October 24, 2018
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Pageof 27